In patients with stage IV pancreas cancer treated with chemotherapy, contrast-enhanced dual-energy CT may provide a useful parameter for survival prediction

A new study from European Radiology demonstrated that the extracellular volume fraction, assessed with contrast-enhanced dual-energy CT at the equilibrium phase, can predict survival in patients suffering from stage IV pancreas cancer and treated with chemotherapy; therefore, this parameter may represent an innovative imaging biomarker.


Log in with your credentials

Forgot your details?